# Neoadjuvant systemic therapy and the surgical management of breast cancer.

**Autores:** Waljee JF, Newman LA
**Revista:** Surg Clin North Am (2007)
**PMID:** 17498534 | **PMCID:** —
**DOI:** [10.1016/j.suc.2007.02.004](https://doi.org/10.1016/j.suc.2007.02.004)
**Fuente:** PubMed (abstract only — full text vía DOI)

## Relevancia
Aporta evidencia sobre la respuesta axilar y la factibilidad de cirugía axilar conservadora en cáncer de mama inflamatorio tratado con NAC, contexto clásicamente excluido de los estudios de SLNB.

## Abstract
Neoadjuvant chemotherapy is standard management for women who have locally advanced or inflammatory breast cancer, but can be applied to all women who may require postoperative chemotherapy for early-stage breast cancer. Disease-free survival and overall survival are equivalent between patients treated with neoadjuvant chemotherapy and patients treated with the same regimen postoperatively. Preoperative chemotherapy can offer women less morbid surgical treatment by down-staging both the primary breast tumor and axillary metastases. Finally, response to chemotherapy can inform clinicians of the chemosensitivity of the tumor, and can predict long-term outcome for women who have breast cancer.

## Acceso
Vía [DOI](https://doi.org/10.1016/j.suc.2007.02.004) o suscripción institucional.

---
*Datos de PubMed. Citar: doi 10.1016/j.suc.2007.02.004*
